Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Starpharma has entered into a collaborative research agreement with Eli Lilly and Company to co-develop one of Starpharma’s dendrimer-drug conjugates.
Subscribe to our email newsletter
The latest agreement follows on the agreement entered in February 2010, in which Starpharma stated that its dendrimer drug delivery technology will be applied to enhance compounds in Lilly’s human pharmaceutical portfolio.
As per the terms of the agreement, Lilly is expected to receive an option on the
conjugate, will pay research fees to Starpharma and will conduct studies in animal models to advance the compound.
Starpharma CEO Jackie Fairley said that they were delighted that Lilly has chosen to expand the scope of its partnership with them once again.
“The agreement follows on from an initial evaluation in animal models of this conjugate by Lilly,” Fairley said.